ATHE ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 October 2024 at 4:30 a.m. AEDT in Australia.

A link to the live and archived webcast may be accessed on the Alterity website under the Investors section: . An archive of the webcast will be available for three months.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia

Ana Luiza Harrop



U.S.

Remy Bernarda



+1 (415) 203-6386



EN
14/10/2024

Underlying

ATHEALTERITY THERAPEUTICS LIMITED

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALTERITY THERAPEUTICS LIMITED

 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chie...

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor – Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise – MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will al...

March 4, 2026 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awarene...

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments – Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes Multiple System Atrophy (MSA...

March 2, 2026 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Repor...

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers...

January 30, 2026 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Prog...

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advan...

January 21, 2026 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual...

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies.  Presentation details AUSTRALIA PARTICIPANTS:Date:Wed...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch